Amfenac Sodium Monohydrate
CAS No. 61618-27-7
Amfenac Sodium Monohydrate( Amfenac sodium H2O )
Catalog No. M15326 CAS No. 61618-27-7
Amfenac Sodium monohydrate is a non-steroidal analgesic anti-inflammatory drug with acetic acid moiety.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 100MG | 31 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 69 | In Stock |
|
| 1G | 100 | In Stock |
|
Biological Information
-
Product NameAmfenac Sodium Monohydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionAmfenac Sodium monohydrate is a non-steroidal analgesic anti-inflammatory drug with acetic acid moiety.
-
DescriptionAmfenac Sodium monohydrate is a non-steroidal analgesic anti-inflammatory drug with acetic acid moiety.(In Vitro):Cells transfected to express COX-2 have a higher proliferation rate than those do not. The addition of Amfenac Sodium Hydrate significantly decreases the proliferation rate of all cell lines. Nitric oxide production by macrophages is inhibited by the addition of melanoma conditioned medium, the addition of Amfenac Sodium Hydrate partially overcomes this inhibition. Results show that Amfenac Sodium Hydrate inhibits the release of B-glucuronidase: 5×10-4 M Amfenac Sodium Hydrate inhibits the release of the enzyme 35.3 and 16.3% in the presence of 10-8, and 10-7 M FMLP, respectively. Addition of 10-4 M Amfenac Sodium Hydrate causes 28.3% inhibition of aggregation of polgmorphonuclear leukocgtes (PMNs) during incubation for 16 min with 10-8 M FMLP.
-
In VitroCells transfected to express COX-2 have a higher proliferation rate than those do not. The addition of Amfenac Sodium Hydrate significantly decreases the proliferation rate of all cell lines. Nitric oxide production by macrophages is inhibited by the addition of melanoma conditioned medium, the addition of Amfenac Sodium Hydrate partially overcomes this inhibition. Results show that Amfenac Sodium Hydrate inhibits the release of B-glucuronidase: 5×10-4 M Amfenac Sodium Hydrate inhibits the release of the enzyme 35.3 and 16.3% in the presence of 10-8, and 10-7 M FMLP, respectively. Addition of 10-4 M Amfenac Sodium Hydrate causes 28.3% inhibition of aggregation of polgmorphonuclear leukocgtes (PMNs) during incubation for 16 min with 10-8 M FMLP.
-
In Vivo——
-
SynonymsAmfenac sodium H2O
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX-1| COX-2
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number61618-27-7
-
Formula Weight295.27
-
Molecular FormulaC15H12NO3·H2O·Na
-
Purity>98% (HPLC)
-
SolubilityEthanol: 4 mg/mL (13.54 mM); Water: 59 mg/mL (199.81 mM); DMSO: 59 mg/mL (199.81 mM)
-
SMILESO=C([O-])CC1=CC=CC(C(C2=CC=CC=C2)=O)=C1N.[H]O[H].[Na+]
-
Chemical NameBenzeneacetic acid, 2-amino-3-benzoyl-, sodium salt, monohydrate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gamache DA, et al. Inflammation, 2000, 24(4), 357-370.
molnova catalog
related products
-
Valdecoxib
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke.
-
Canolol
Canolol is an antioxidant phenolic compound that has potential use as a COX-2 inhibitor.
-
Amtolmetin guacil
Amtolmetin guacil inhibits prostaglandin synthesis and cyclooxygenase. Amtolmetin guacil has similar NSAID properties like tolmetin with additional analgesic, antipyretic, and gastroprotective properties.
Cart
sales@molnova.com